BELLUS Health, Inc.
(Toronto Stock Exchange : BLU)

( )
BLU PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.16%162.160.7%$1270.30m
LLYEli Lilly & Co. 0.50%334.461.1%$1111.09m
ABBVAbbVie, Inc. 0.01%140.301.9%$860.61m
PFEPfizer Inc. 0.16%43.180.9%$804.94m
BMYBristol-Myers Squibb Co. -0.04%70.211.0%$751.47m
MRKMerck & Co., Inc. -0.37%87.110.7%$695.02m
AZNAstraZeneca Plc 2.04%56.031.0%$394.07m
ALNYAlnylam Pharmaceuticals, Inc. 0.00%202.378.2%$224.83m
GSKGSK Plc 1.70%30.510.3%$212.06m
NVSNovartis AG 0.54%76.450.2%$201.99m
HZNPHorizon Therapeutics Plc 0.00%67.895.4%$188.70m
IDXXIDEXX Laboratories, Inc. 0.00%346.023.9%$184.33m
GBTGlobal Blood Therapeutics, Inc. 0.00%68.495.4%$178.81m
SRPTSarepta Therapeutics, Inc. 0.00%114.8212.4%$141.73m
AKROAkero Therapeutics, Inc. 0.00%39.260.0%$134.17m

Company Profile

BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.